Reduced vancomycin susceptibility in porcine ST9 MRSA isolates by Gabriella M. L. Kwok et al.
ORIGINAL RESEARCH ARTICLE
published: 25 October 2013
doi: 10.3389/fmicb.2013.00316
Reduced vancomycin susceptibility in porcine ST9 MRSA
isolates
Gabriella M. L. Kwok1, Margaret M. O’Donoghue2, Vijaya C. Doddangoudar1, Jeff Ho2 and
Maureen V. Boost1*
1 Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong
2 School of Nursing, The Hong Kong Polytechnic University, Kowloon, Hong Kong
Edited by:
Axel Cloeckaert, Institut National de
la Recherche Agronomique, France
Reviewed by:
Patrick R. Butaye, Ghent University,
Belgium
Seamus Fanning, University College
Dublin, Ireland
*Correspondence:
Maureen V. Boost, Department of
Health Technology and Informatics,
The Hong Kong Polytechnic
University, Kowloon, Hong Kong
e-mail: maureen.boost@
polyu.edu.hk
Porcine strains of livestock-associated methicillin resistant Staphylococcus aureus
(LA-MRSA) have been recognized in many countries and have been shown to be able
to cause human infection. Resistance to non-beta lactam antibiotics has been reported
but non-susceptibility to vancomycin, which is known to occur in human MRSA, has so
far not been observed in LA-MRSA. Such resistance is typically fairly low level involving
changes in the cell wall thickness. The development of resistance is usually preceded by
presence of a sub-population having an increased MIC, which is selected for by exposure
to vancomycin. This study investigated vancomycin susceptibility of one hundred porcine
MRSA isolates using threeMICmethods including spiral gradient endpoint (SGE) technique
which allows visualization of more resistant sub-populations. SGE revealed 16 strains with
an MIC above 2.0mg/L, of which 14 were determined to have MIC 4mg/L by agar dilution
(AD). SGE revealed a further two isolateswithMIC< 2mg/L had a sub-population>2mg/L.
In addition, trailing endpoints not reaching resistance were present in 26 isolates with
MIC < 2mg/L. Sequencing of the genes of the VraSR/GraSR two component systems
of ten of the resistant strains for comparison with susceptible strains revealed changes,
including the presence of stop codons, in vraS and graR, but these were not consistent
in all isolates. Other genetic changes may contribute to vancomycin non-susceptibility
and require investigation. As failure to respond to treatment has been reported in clinical
isolates with MIC > 1.5mg/L, the presence of vancomycin non-susceptibility in porcine
isolates is of concern and further monitoring of LA-MRSA is essential.
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INTRODUCTION
Methicillin resistant Staphylococcus aureus (MRSA) has long been
an important hospital-associated pathogen, but its emergence
in the community and, more recently, in livestock has led to
increasing concern. Livestock-associatedMRSA (LA-MRSA), first
recognized in the Netherlands (Voss et al., 2005), has now been
reported from many locations, including Asia (Denis et al., 2009;
Guardabassi et al., 2009; Smith et al., 2009; Larsen et al., 2012).
However, Asian isolates differ from those of Europe, belong-
ing almost exclusively to ST9 (Cui et al., 2009; Guardabassi
et al., 2009; Neela et al., 2009), rather than ST398 which is
the most prevalent lineage in Europe and North America. In
addition, Asian isolates are more likely to be multi-drug resis-
tant, displaying resistance to up to eight agents (Ho et al.,
2012). To date it appears that LA-MRSA strains are less viru-
lent than human isolates and, although these strains do colo-
nize and occasionally cause infections in man, their human-to
human transmission risk is much lower than that of typical
MRSA (Bootsma et al., 2011). However, their ability to cause
infection does increase concern, as their antibiotic resistance pro-
file is extensive leading to limited choices of therapy. To date
there have not been any reports of resistance to vancomycin in
LA-MRSA, though non-susceptibility to this drug has frequently
been reported in typical human MRSA isolates (Howden et al.,
2010).
Most vancomycin resistance in S. aureus involves changes that
result in thickening of the bacterial cell wall, sometimes termed
intermediate resistance, rather than by acquisition of the vanA
gene observed in high level resistance (Howden et al., 2010). The
thickening of the cell wall has been attributed to mutations of
regulatory genes including those of the two component systems
vraSR/graSR, and walK as well as rpoB, with a large number of
the studies reporting changes in vraS and graR (Neoh et al., 2008;
Cui et al., 2009; Doddangoudar et al., 2011, 2012; Galbusera et al.,
2011). Vancomycin intermediately-resistant S. aureus (VISA),
has been redefined as vancomycin resistant S. aureus (VRSA)
since the revision of the European Committee for Antimicrobial
Susceptibility Testing guidelines (EUCAST, 2013). The change
was justified by the recognition of treatment failures in infections
attributable to isolates with MIC of 2mg/L (Lodise et al., 2008).
Strains with more resistant sub-populations, first recognized in
Japan (Hiramatsu et al., 1997), are referred to as heterogeneous
vancomycin intermediately resistant S. aureus (hVISA) but are
not clearly defined in EUCAST guidelines. Such strains may
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rapidly progress to VRSA in the presence of vancomycin (Howden
et al., 2010).
Testing for vancomycin non-susceptibility requires accurate
determination of the MIC. Many of the standard methods have
been criticized either for their lack of accuracy or reproducibility
or because the large increments between dilutions makes smaller
changes more difficult to detect. The use of the spiral gradient
endpoint (SGE) technique can overcome these difficulties and
this method has been shown to produce reliable results with excel-
lent correlation with the CLSI recommended dilution method
(Doddangoudar et al., 2010).
This study determined the prevalence of vancomycin non-
susceptibility in LA-MRSA isolates from slaughtered pigs and
comparedsequencesofvraSandgraRofresistant isolateswiththose
of both sensitive strains, a known vancomycin intermediately-
resistant strain (Mu50), anda control vancomycin sensitiveMRSA.
MATERIALS AND METHODS
One hundred MRSA (ST9) previously isolated from slaughtered
pigs originating in China (Ho et al., 2012) were investigated
for reduced vancomycin susceptibility. Although, these strains
had been previously tested for vancomycin resistance by broth
microdilution (BMD), with none giving an MIC > 2mg/L (Ho
et al., 2012), later testing of a few isolates using agar dilution
(AD) and SGE for a separate study suggested that some could
have MICs above 2mg/L or harbor a resistant sub-population.
The strains, which had been stored at −80◦C, were subcultured
on brain heart infusion (BHI) agar and the MIC for vancomycin
determined using the SGE technique (Doddangoudar et al., 2010)
and AD (Clinical Laboratory Standards Institute, 2012).
SGE was performed by dispensing 50µL of a 1072mg/L
vancomycin stock solution on a BHI agar plate using a spiral
plater (Autoplate 4000, Spiral-Biotech, Advanced Instruments,
Norwood, MA, USA) to produce a concentration gradient of
0.5–8mg/L on each plate. The plates were allowed to rest for
1.5 h to allow the gradient to develop. Each porcine isolate was
inoculated into 2mL BHI broth and incubated at 37◦C to achieve
a turbidity equivalent to a 0.5 McFarland standard. These inocula
were streaked across the prepared vancomycin gradients, each
specimen being performed in duplicate as is standard practice for
this method (Doddangoudar et al., 2010). The plates were incu-
bated for24 handtheendpointofgrowthwasdeterminedusing the
SGE template available from Spiral Biotech. Control strains, N315
(vancomycin sensitive MRSA: VSSA), and NRS1 (Mu50: VISA)
were included in every test batch. Both the confluent endpoint
(EC)ofgrowthand thepresenceandextentof any trailingendpoint
(TEC) were noted. The EC concentration, which was equivalent
to the vancomycin MIC, was determined using the SGE software
(Spiral Biotech). A TEC, with higher inhibitory concentration,
may indicate the presence of a more resistant sub-population of
the strain as is reported in hVISA strains. MICs were interpreted
for both AD and SGE using EUCAST guidelines (EUCAST, 2013).
To confirm accuracy of SGE, 20 isolates were repeated in duplicate
1 week after completion of the initial MIC testing.
Glycopeptide resistance detection (GRD) Etest (Yusof et al.,
2008) and macro Etest (MET) (Walsh et al., 2001) were used for
the isolates with TECs as further tests to detect hVISA. AD and
SGE were incubated for 24 h, but incubation was extended to 48 h
for MET and GRD.
Following MIC determination, DNA was extracted from the
10 isolates with highest MICs. N315 and a vancomycin sensitive
porcineisolate(MIC1.0mg/L)wereincludedascontrols.BothvraS
and graR were amplified as previously described (Doddangoudar
et al., 2011) and visualized by agarose gel electrophoresis and
ethidium bromide staining. The amplicons were cleansed by
treatment with 0.05µL of 20U/µL exonuclease (Thermo-Fisher,
Pittsburgh, PA, USA) and 1µL of 1 IU/µL shrimp alkaline phos-
phatase (Thermo-Fisher) at 37◦C for 30min followed by 15min
at 80◦C, before sequencing. Sequences from porcine isolates were
compared with those of N315 and Mu50 using multiple sequence
alignment software (Corpet, 1988), base changes being catego-
rized as silent or non-synonymous mutations. Sequences of the
vancomycin susceptible and non-susceptible porcine isolates were
also compared to determine if there were any common changes
between susceptible and non-susceptible isolates and amongst
non-susceptible isolates.
RESULTS
Low level non-susceptibility was observed in 16 isolates which
displayed MIC values ranging from 2.1 to 2.3mg/L vancomycin
by SGE. Of these, 14 isolates displayed growth on AD plates
at 2mg/L, thus, were reported as MIC 4mg/L. The remaining
two strains were inhibited, but grew well at 1mg/L, thus, having
an MIC of 2mg/L by the standard method. Of the 16 strains
having an elevated MIC, five displayed a TEC with a higher value
indicating the presence of a more resistant sub-population. SGE
revealed a further two isolates with an EC below two (1.8mg/L)
displayed TEC above 2mg/L suggesting that these strains had a
more resistant sub-population (Table 1). Testing of the five strains
with MIC > 2mg/L and displaying a TEC using GRD and MET
did not result in any of these having an MIC ≥ 8.0mg/L, but
microcolonies were present in the clear area showing presence of
more resistant sub-populations in all five by MET and three using
GRD. Comparisons of MICs by BMD (Ho et al., 2012), AD, and
SGE are shown in Figure 1.
In addition to the presence of resistant strains, the overall
average MIC was relatively high (1.8mg/L) and strains classed
as VSSA had an average MIC of 1.7mg/L (Table 1). TECs with
MICs below 2mg/L were present in 26/82 (32%) of the VSSA
strains. The MIC values obtained for the control strains NRS1
and N315, which were performed for every batch tested, were in
the expected range (8.5 and 1.1mg/L) and repeated estimations
of 20 of the samples showed <10% differences in MIC values,
indicating SGE provided reliable and accurate results.
Visualization of the amplicons of the 10 samples with highest
MIC values and the control strains revealed clear bands situated
between 1000 and 1650 bp for vraS and between 650 and 850 bp
for graR on the DNA ladder which were similar to the target gene
sizes of 1041 and 672 bp reported for these genes. Comparison
of sequences revealed non-synonymous changes in vraS in three
isolates. InM1(VSSA)adeletionatbase741resulted ina frameshift
and generation of a novel stop codon at amino acid 278. In two
of the resistant strains, M7 and M10, V275STOP, and N279I were
observed, respectively (Table 2). Changes in comparison to the
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Table 1 | Minimum inhibitory concentrations (MIC) to vancomycin of porcine MRSA isolates by SGE.
Classification Number of isolates Average MIC − EC Range EC Average MIC − TEC Range TEC MIC50 MIC90
VSSAa 82 1.7 1.2–1.9 1.8d 1.5–1.9
VSSAc 2 1.8 1.8 2.2 2.2
VRSAa,b 16 2.1 2.1–2.3 2.5e,f 2.2–3.0
Overall 100 1.8 1.2–2.3 1.9 1.5–3.0 1.8 2.1
EC—confluent endpoint concentration which represents the MIC of the majority of the population.
TEC—trailing endpoint concentration which represents the MIC of the sub-population.
aEUCAST definition (2009) sensitive (VSSA): ≤ 2mg/L; resistant (VRSA): = MIC > 2.0 mg/L.
b14 of these strains gave MIC 4 mg./L by AD.
cEC MIC ≤ 2mg/L, TEC > 2mg/L.
d Present in 26 isolates (not >2 mg/L).
ePresent in 5 isolates, three of which were 2.5 mg/L. (all showed micro-colonies in MET).
f Three of these showed microcolonies in GRD.
FIGURE 1 | Comparison of vancomycin MICs of porcine MRSA by
broth microdilution (BMD) [from Ho et al. (2012)], agar dilution (AD),
and spiral gradient endpoint technique (SGE). #Two isolates displayed
a sub-population above 2.0mg/L (hVISA). ∗Five isolates displayed
sub-populations by Macro Etest; of these, three isolates displayed
sub-populations by Glycopeptide Resistance Detection. The latter three
strains displayed a TEC MIC for SGE of = 2.5mg/L, the remaining two
had TEC < 2.5mg/L.
controls were also noted in graR in the VSSA isolate, M1. There
were four successive mutations at base numbers 672 − 5, leading
to a E224D missense mutation, followed by three consecutive
mutations leading to insertion of a codon coding for isoleucine,
at the position where the stop codon should be thereby elongating
the amino acid chain by one amino acid before the stop codon.
Several mutations were observed in the non-susceptible strains,
with V6L and E15K both present in four strains, and E120D in
three. Stop codons were present in both M3 and M9 and other
unique mutations were observed in M7 and M11 (Table 2).
DISCUSSION
Whilst vancomycin non-susceptibility has been reported in several
countries and there have been a number of reports of treatment
failure for human clinical isolates, this study appears to be the
first to describe reduced susceptibility in MRSA of porcine origin.
There have been several reports describing human colonization
and infection with porcine strains (Voss et al., 2005; van der
Mee-Marquet et al., 2011) and elevated vancomycin MICs as
observed in our isolates would render treatment with vancomycin
more prone to fail (Lodise et al., 2008; Jacob and Diazgranados,
2013). Overall, 16% of isolates appeared to have reduced sus-
ceptibility with MICs above 2.0mg/L using SGE, and 14% by
AD. In addition, the overall average MIC was close to the break-
point by all three MIC methods used. These strains should not
have been exposed to glycopeptides, since use of avoparcin has
been banned in China, as elsewhere, for more than a decade,
due to concerns of its contribution to development of bacterial
resistance (Witte, 1998). Reports of clinical infections caused by
vancomycin-resistant enterococci in both humans and animals
dropped dramatically in Europe and Taiwan after the ban (Sørum
et al., 2006; Lauderdale et al., 2007). It is possible that glycopep-
tides other than avoparcin are in use thereby circumventing the
ban on a specific agent. Alternatively, the feeding of mycelium,
which is practiced in China, may provide antibiotic agents (Witte,
1998). However, it has also been suggested that use of antibiotics
other than glycopeptides may lead to increases in resistance to
vancomycin (Katayama et al., 2009; Tattevin et al., 2009). The high
rate of non-susceptibility suggests that there has been some antibi-
otic exposure during production and it is common to supplement
animal feed with low doses of antibiotics both for prophylaxis
and growth promotion. Although the 40%MRSA contamination
rate of pig carcasses observed in Hong Kong (Ho et al., 2012) is
similar to reported rates in Europe (de Neeling et al., 2007), local
isolates tend to be resistant to more non-beta-lactam antibiotics.
SGE technique detected a more resistant sub-population in
a high percentage of strains. If these are indeed representative
of populations with reduced vancomycin susceptibility, this is
of concern. In clinical isolates, such heterogeneous strains have
been associated with a rapid increase in vancomycin resistance in
the presence of the drug and subsequent treatment failure (Rong
and Leonard, 2010). Recognition of hVISA remains difficult and
several studies have reported different outcomes for the various
methods available for detection (Riederer et al., 2011; Satola
et al., 2011). Whilst not being recognized as a reference method,
SGE does allow easy visualization of sub-populations by 24 h
in the form of trailing endpoints (Doddangoudar et al., 2010),
which can be missed by other methods (Leonard et al., 2009;
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Table 2 | Presence of mutations observed in one vancomycin susceptible (M1) and 10 vancomycin non-susceptible (M2–11) porcine isolates
in comparison with N315 (control MRSA).
Mutation Sample number
Sample M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11
Vancomycin MIC 1.4 2.2 2.2 2.2 2.1 2.3 2.1 2.2 2.1 2.1 2.1
By SGE (TEC) (−) (3.0) (−) (−) (2.5) (−) (2.5) (−) (2.2) (−) (−)
vraS
F278STOP + − − − − − − − − − −
V275STOP − − − − − − + − − − −
N279I − − − − − − − − − + −
graR
I206STOP − − + − − − − − − − −
E224D + − − − − − − − E224STOP − −
STOP225I + − − − − − − − − − −
V6L − − + + − − − + + − −
E19K − − + − − − − + + − +
E120D − − + − − − − − + + −
V216STOP − − − − − − + − − − −
E15K − − − − − − − − − − +
R117R − − − − − − − − − − +
D133N − − − − − − − − − − +
A185P − − − − − − − − − − +
L203STOP − − − − − − − − − − +
van Hal et al., 2011). Investigation of the five strains having an
MIC > 2.0mg/L and a TEC by SGE using phenotypic methods
of hVISA recognition did not yield MIC values which met the
definition of hVISA, but revealed presence of microcolonies in
the clear areas for three by GRD and in all five byMET after a 48 h
incubation period. Although the GRD/MET MIC results did not
confirm the isolates as hVISA, the presence of microcolonies has
been suggested to reflect the presence ofmore resistant individuals
in the population (Howden et al., 2010). Further studies may help
to determine if a TEC does correlate with presence of a more
resistant sub-population.
ThestrainsdesignatedasvancomycinresistantbySGEwereonly
marginally above the breakpoint and the evaluation of themethod
has shown a CV of 10% (Doddangoudar et al., 2010). However,
this margin of error could move strains across the breakpoint as
the vast majority were clustered around this level. This limitation
of accuracy also applies to all MIC detection methods. It is of
note that all three methods used showed clustering around the
breakpoint indicating increases in resistance and results from
AD closely matched those of SGE. Notably, BMD previously
performed on these isolates (Ho et al., 2012) had not indicated
any vancomycin resistance.However, several studies have reported
that BMD may fail to detect vancomycin non-susceptible strains
which are evident by Etest or AD (Walsh et al., 2001; Nadarajah
et al., 2010; Vaudaux et al., 2010).
Porcine MRSA are widely distributed in the production chain
and MRSA ST9 has been isolated locally from butchers (Boost
et al., 2012) aswell as fromchoppingboards (Lee et al., 2012), retail
meats (Boost et al., 2013), and roasted pork (Young et al., 2012).
Other studies on resistance of LA-MRSA have mainly focused
on ST398, but none have reported resistance to vancomycin.
The need for performing an MIC method to detect vancomycin
resistance may discourage investigation of susceptibility and some
studies still report use of disc diffusion methods for this agent.
Alternatively, such resistancemay bemore typical of Asian isolates
of ST9, which display more resistance to other non-beta-lactam
antibiotics (Ho et al., 2012).
It has been demonstrated that a point mutation in vraS can
lead to activation of vraR and development of hVISA (Cui et al.,
2009) and that a mutation in graR results in thickening of the cell
wall and conversion of hVISA to VISA (Neoh et al., 2008). These
changes have been observed in a local clinical isolate of VISA
and in six MRSA strains which were induced with vancomycin
(Doddangoudaretal.,2011,2012).However,oftheinducedisolates
with reduced susceptibility, changes in vraS were only present in
two, one demonstrating a mutation in vraS, and a second having
a stop codon. Similar changes have been noted in vraS in a clinical
isolate of VISA (Doddangoudar et al., 2011). In the present study,
seven of the 10 non-susceptible strains showed a mutation in
graR and two of these also had a stop codon as a result of a frame
shift. One of the stop codons has previously been observed in
induced strains (Doddangoudar et al., 2012). However, the lack of
mutations in some of the non-susceptible porcine isolates suggests
that changes in the VraSR/GraSR component systems alone may
not explain the phenomenon of reduced susceptibility in these
strains. Other workers have examined other regulatory genes
in clinical isolates displaying reduced vancomycin susceptibility
including rpoB, walk, and clf, but none of these has been shown
to be present in all strains (Howden et al., 2011; Shoji et al., 2011;
Watanabe et al., 2011;Hafer et al., 2012). It has been suggested that
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certain mechanisms may be more common in some clones or
in some geographic regions (Hafer et al., 2012), with vraSR or
graSR having SNPs in ST8, whereas ST5 demonstrated changes
in walk.
However, an alternative explanation may be that the strains
are in the process of losing vancomycin non-susceptibility. It has
been demonstrated that strains which have been exposed to van-
comycin become non-susceptible to this agent, but rapidly revert
to susceptibility if the drug pressure is removed (Doddangoudar
et al., 2012; Ludwig et al., 2012). This loss of susceptibility may be
accompanied by appearance of STOP codons in the vraSR/graSR
two component systems (Doddangoudar et al., 2012). In this
study, stop codons were present in vraS of one and in graR of four
porcine non-susceptible strains and interestingly in both genes
of the strain used as a porcine negative control. It is therefore,
possible that these strains were in the process of reversion to
susceptibility in the absence of vancomycin and that the overall
elevated MICs of the isolates reflects a population which is losing
resistance.
This studyhas shownthatLA-MRSAstrainscandisplay reduced
susceptibility to vancomycin, even if currently MIC levels are only
slightly above the breakpoint. Problems of treatment failure have
been reported in clinical isolates with similar MICs and so cau-
tion with LA-MRSA is necessary. The lack of a consistent genetic
markerforvancomycinlowlevelresistancemakesdetectionofthese
organisms difficult and there is a need for further investigation
of changes in other regulatory systems in porcine isolates.
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